FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Veronica Miller

Research Profile

Disorders

HIV Infections

Chemicals & Drugs

Living Beings

HIV-1

Concepts & Ideas

Procedures

Physiology

Co-author Network

Publications

TOP 3
Victor DeGruttola; Davey M Smith; Susan J Little; Veronica Miller
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges.
Markus Bickel; Volker Rickerts; Christoph Stephan; Volkmar Jacobi; Carsten Rottmann; Brenda Dauer; Amina Carlebach; Axel Thalhammer; Veronica Miller; S Staszweski
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
Alessandro Cozzi-Lepri; Andrew N Phillips; Veronica Miller; Christine Katlama; bruno ledergerber; STEFANO VELLA; Jonathan Weber; Johan Bruun; Ole Kirk; Bonaventura Clotet; Jens D Lundgrens
Changes in viral load in people with virological failure who remain on the same HAART regimen.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Veronica Miller (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Victor DeGruttola; Davey M Smith; Susan J Little; Veronica Miller
Developing and evaluating comprehensive HIV infection control strategies: issues and challenges.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2010;50 Suppl 3():S102-7.
2005: Markus Bickel; Volker Rickerts; Christoph Stephan; Volkmar Jacobi; Carsten Rottmann; Brenda Dauer; Amina Carlebach; Axel Thalhammer; Veronica Miller; S Staszweski
The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.
HIV medicine 2005;6(3):179-84.
2003: Alessandro Cozzi-Lepri; Andrew N Phillips; Veronica Miller; Christine Katlama; bruno ledergerber; STEFANO VELLA; Jonathan Weber; Johan Bruun; Ole Kirk; Bonaventura Clotet; Jens D Lundgrens
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2002: Andrew N Phillips; Schlomo Staszewski; Fiona C Lampe; Mike Youle; Stephan Klauke; Markus Bickel; Caroline A Sabin; Hans Wilhelm Doerr; Margaret A Johnson; Clive Loveday; Veronica Miller
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
The Journal of infectious diseases 2002;186(8):1086-91.
2002: Veronica Miller; Andrew N Phillips; Bonaventura Clotet; Amanda Mocroft; bruno ledergerber; Ole Kirk; Vidar Ormaasen; Panagiotis Gargalianos-Kakolyris; STEFANO VELLA; Jens D Lundgren
Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
The Journal of infectious diseases 2002;186(2):189-97.
2001: Andrew N Phillips; Veronica Miller; Caroline Sabin; Alessandro Cozzi-Lepri; Stephan Klauke; Markus Bickel; Hans Wilhelm Doerr; A Hill; Schlomo Staszewski
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.
AIDS (London, England) 2001;15(18):2379-84.
2001: P Richard Harrigan; Julio S G Montaner; Scott Wegner; Werner Verbiest; Veronica Miller; R Wood; Brendan Larder
World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing.
AIDS (London, England) 2001;15(13):1671-7.
2001: Ole Kirk; Amanda Mocroft; C Pradier; JN Bruun; R Hemmer; Bonaventura Clotet; Veronica Miller; Jean-Paul Viard; Andrew N Phillips; Jens D Lundgren
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
AIDS (London, England) 2001;15(8):999-1008.
2001: Veronica Miller
International perspectives on antiretroviral resistance. Resistance to protease inhibitors.
Journal of acquired immune deficiency syndromes (1999) 2001;26 Suppl 1():S34-50.
2001: Amanda Mocroft; Andrew N Phillips; Veronica Miller; José M Gatell; Jan van Lunzen; J M Parkin; R Weber; B Roge; Adriano Lazzarin; Jens D Lundgren
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
AIDS (London, England) 2001;15(2):201-9.
2001: Alessandro Cozzi Lepri; Veronica Miller; Andrew N Phillips; Holger Rabenau; Caroline A Sabin; Schlomo Staszewski
The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.
AIDS (London, England) 2001;15(1):47-54.
2001: Veronica Miller
Interpretation of resistance assay results.
Antiviral therapy 2001;6 Suppl 2():1-9.
2001: Veronica Miller; Brendan Larder
Mutational patterns in the HIV genome and cross-resistance following nucleoside and nucleotide analogue drug exposure.
Antiviral therapy 2001;6 Suppl 3():25-44.
2000: Veronica Miller; Caroline Sabin; Kurt Hertogs; Stuart Bloor; Javier Martinez-Picado; Richard T D'Aquila; Brendan Larder; Thomas Lutz; Peter Gute; Eckhart Weidmann; Holger Rabenau; Andrew Phillips; Schlomo Staszewski
Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure.
AIDS (London, England) 2000;14(18):2857-67.
2000: Veronica Miller; C A Sabin; Andrew N Phillips; Carsten Rottmann; Holger Rabenau; Eckhart Weidmann; Volker Rickerts; S Findhammer; Eilke B Helm; Schlomo Staszewski
The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
AIDS (London, England) 2000;14(14):2129-36.
2000: Schlomo Staszewski; Annette Haberl; Amina Carlebach; Carsten Rottmann; Veronica Miller; Peter Gute
A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.
HIV medicine 2000;1(3):162-3.
2000: Bettina Gröschel; Veronica Miller; Hans Wilhelm Doerr; Jindrich Cinatl
Activity of cellular thymidine kinase 1 in PBMC of HIV-1-infected patients: novel therapy marker.
Infection 2000;28(4):209-13.
2000: Kurt Hertogs; Stuart Bloor; SD Kemp; Christel Van den Eynde; TM Alcorn; Rudi Pauwels; M Van Houtte; Schlomo Staszewski; Veronica Miller; Brendan Larder
Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples.
AIDS (London, England) 2000;14(9):1203-10.
2000: Amanda Mocroft; Veronica Miller; Antonio Chiesi; Anders Blaxhult; Christine Katlama; Bonaventura Clotet; S Barton; Jens D Lundgren
Virological failure among patients on HAART from across Europe: results from the EuroSIDA study.
Antiviral therapy 2000;5(2):107-12.
2000: Veronica Miller; Alessandro Cozzi-Lepri; Kurt Hertogs; Peter Gute; Brendan Larder; Stuart Bloor; Stephan Klauke; Holger Rabenau; Andrew Phillips; Schlomo Staszewski
HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort.
Antiviral therapy 2000;5(1):49-55.
2000: Victor DeGruttola; L Dix; Richard T D'Aquila; D Holder; A Phillips; Mounir Ait-Khaled; J Baxter; Philippe Clevenbergh; S Hammer; R Harrigan; David Katzenstein; R Lanier; M Miller; Michael F Para; S Yerly; Andrew R Zolopa; J Murray; A Patick; Veronica Miller; S Castillo; Louise Pedneault; John Mellors
The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan.
Antiviral therapy 2000;5(1):41-8.
2000: Alessandro Cozzi-Lepri; Caroline A Sabin; Schlomo Staszewski; Kurt Hertogs; A Müller; Holger Rabenau; Andrew N Phillips; Veronica Miller
Resistance profiles in patients with viral rebound on potent antiretroviral therapy.
The Journal of infectious diseases 2000;181(3):1143-7.
2000: Kurt Hertogs; Stuart Bloor; Veronique De Vroey; Christel Van den Eynde; Pascale Dehertogh; A Van Cauwenberge; Martin Stürmer; TM Alcorn; Scott Wegner; M Van Houtte; Veronica Miller; Brendan Larder
A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V.
Antimicrobial agents and chemotherapy 2000;44(3):568-73.
2000: N Holtkamp; A Otteken; S Findhammer; Veronica Miller; Reinhard Kurth; A Werner
Unexpected coreceptor usage of primary human immunodeficiency virus type 1 isolates from viremic patients under highly active antiretroviral therapy.
The Journal of infectious diseases 2000;181(2):513-21.
2000: Veronica Miller; Mounir Ait-Khaled; Chris Stone; Philip Griffin; D Mesogiti; Amy Cutrell; RP Harrigan; Schlomo Staszewski; Christine Katlama; Gillian Pearce; Margaret Tisdale
HIV-1 reverse transcriptase (RT) genotype and susceptibility to RT inhibitors during abacavir monotherapy and combination therapy.
AIDS (London, England) 2000;14(2):163-71.
1999: Antonio Chiesi; Amanda Mocroft; L G Dally; Veronica Miller; Christine Katlama; bruno ledergerber; C Pedersen; Andrew N Phillips; Romano Arcieri; Jens D Lundgren
Regional survival differences across Europe in HIV-positive people: the EuroSIDA study.
AIDS (London, England) 1999;13(16):2281-8.
1999: Brendan Larder; Stuart Bloor; SD Kemp; Kurt Hertogs; R L Desmet; Veronica Miller; M Sturmer; Schlomo Staszewski; J Ren; David K Stammers; D I Stuart; Rudi Pauwels
A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance.
Antimicrobial agents and chemotherapy 1999;43(8):1961-7.
1999: Veronica Miller; Schlomo Staszewski; Caroline Sabin; Amina Carlebach; Carsten Rottmann; Eckhart Weidmann; Holger Rabenau; A Hill; Alessandro Cozzi Lepri; Andrew N Phillips
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
The Journal of infectious diseases 1999;180(2):530-3.
1999: Schlomo Staszewski; Veronica Miller; Caroline Sabin; C Schlecht; Peter Gute; Stefan Stamm; T Leder; A Berger; E Weidemann; A Hill; Andrew Phillips
Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy.
AIDS (London, England) 1999;13(8):951-6.
1999: Schlomo Staszewski; Veronica Miller; Caroline Sabin; Amina Carlebach; A M Berger; Eckhart Weidmann; Eilke B Helm; A Hill; Andrew Phillips
Virological response to protease inhibitor therapy in an HIV clinic cohort.
AIDS (London, England) 1999;13(3):367-73.
1999: Veronica Miller; Schlomo Staszewski; Gaby Nisius; Alessandro Cozzi Lepri; Caroline Sabin; Andrew N Phillips
Risk of new AIDS diseases in people on triple therapy.
Lancet 1999;353(9151):463.
1999: Carsten Rottmann; Veronica Miller; Schlomo Staszewski
Mega-HAART: preliminary results and correlation with baseline resistance.
Antiviral therapy 1999;4 Suppl 3():93-4.
1998: Schlomo Staszewski; Veronica Miller; Caroline Sabin; A Berger; AM Hill; Andrew N Phillips
Rebound of HIV-1 viral load after suppression to very low levels.
AIDS (London, England) 1998;12(17):2360.
1998: Veronica Miller; Marie-Pierre de Bethune; A Kober; Martin Stürmer; Kurt Hertogs; Rudi Pauwels; P Stoffels; Schlomo Staszewski
Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride.
Antimicrobial agents and chemotherapy 1998;42(12):3123-9.
1998: Amanda Mocroft; STEFANO VELLA; T L Benfield; Antonio Chiesi; Veronica Miller; Panagiotis Gargalianos; Antonella d'Arminio Monforte; Israel Yust; JN Bruun; Andrew N Phillips; Jens D Lundgren
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
Lancet 1998;352(9142):1725-30.
1998: Veronica Miller; Andrew Phillips; Carsten Rottmann; Schlomo Staszewski; Rudi Pauwels; Kurt Hertogs; Marie-Pierre de Bethune; SD Kemp; Stuart Bloor; P Richard Harrigan; Brendan Larder
Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.
The Journal of infectious diseases 1998;177(6):1521-32.
1998: Veronica Miller; Martin Stürmer; Schlomo Staszewski; Bettina Gröschel; Kurt Hertogs; Marie-Pierre de Bethune; Rudi Pauwels; P Richard Harrigan; Stuart Bloor; SD Kemp; Brendan Larder
The M184V mutation in HIV-1 reverse transcriptase (RT) conferring lamivudine resistance does not result in broad cross-resistance to nucleoside analogue RT inhibitors.
AIDS (London, England) 1998;12(7):705-12.
1998: Kurt Hertogs; Marie-Pierre de Bethune; Veronica Miller; Tania Ivens; P Schel; A Van Cauwenberge; Christel Van den Eynde; V Van Gerwen; Hilde Azijn; M Van Houtte; F Peeters; Schlomo Staszewski; Marcus Conant; Stuart Bloor; S Kemp; Brendan Larder; Rudi Pauwels
A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs.
Antimicrobial agents and chemotherapy 1998;42(2):269-76.
1998: Schlomo Staszewski; Annette Haberl; Peter Gute; Gaby Nisius; Veronica Miller; Amina Carlebach
Nevirapine/didanosine/lamivudine once daily in HIV-1-infected intravenous drug users.
Antiviral therapy 1998;3 Suppl 4():55-6.
1997: Veronica Miller; Schlomo Staszewski; C A Boucher; J P Phair
Clinical experience with non-nucleoside reverse transcriptase inhibitors.
AIDS (London, England) 1997;11 Suppl A():S157-64.
1996: Schlomo Staszewski; Veronica Miller; S Rehmet; T Stark; J De Crée; M De Brabander; M Peeters; Koen Andries; M Moeremans; M De Raeymaeker; G Pearce; R Van den Broeck; W Verbiest; P Stoffels
Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients.
AIDS (London, England) 1996;10(5):F1-7.
1996: Schlomo Staszewski; Veronica Miller; A Kober; R Colebunders; B Vandercam; J Delescluse; N Clumeck; F Van Wanzeele; M De Brabander; J De Creé; M Moeremans; Koen Andries; C Boucher; P Stoffels; P A Janssen
Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Loviride Collaborative Study Group.
Antiviral therapy 1996;1(1):42-50.